Among patients with cN2 breast cancer, they found that nodal pCR after NAST was associated with subtype, clinical and radiologic response, and Ki-67 expression, suggesting that SLNB could be recommended for patients with HER2+ or TNBC with cN2 if there is a complete response. The gene discussed is CNDP2; the disease is breast carcinoma.